Clinical Trial

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Protocol Amendment History 34 amendments
This ClinicalTrials.gov record has been amended 34 times since 2021-11-12; most recent amendment 2026-06-30.
Status change: Not Yet Recruiting → Recruiting 2022-03-15
Trial Details
NCT Number NCT05131022
Lead Sponsor Nurix Therapeutics, Inc.
Conditions Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL) +1 more
Enrollment 572 participants
Start Date 2022-04-13
Primary Completion 2027-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-02